vs
Side-by-side financial comparison of Grindr Inc. (GRND) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $126.0M, roughly 1.4× Grindr Inc.). Grindr Inc. runs the higher net margin — 16.1% vs 1.6%, a 14.4% gap on every dollar of revenue. On growth, Grindr Inc. posted the faster year-over-year revenue change (29.0% vs 5.0%). Over the past eight quarters, Grindr Inc.'s revenue compounded faster (29.3% CAGR vs -0.2%).
Grindr is a location-based social networking and online hookup application for LGBTQ people.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GRND vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $126.0M | $177.4M |
| Net Profit | $20.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 24.9% | 3.9% |
| Net Margin | 16.1% | 1.6% |
| Revenue YoY | 29.0% | 5.0% |
| Net Profit YoY | 116.4% | — |
| EPS (diluted) | $0.10 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $126.0M | $196.9M | ||
| Q3 25 | $115.8M | $179.5M | ||
| Q2 25 | $104.2M | $181.1M | ||
| Q1 25 | $93.9M | $168.9M | ||
| Q4 24 | $97.6M | $187.3M | ||
| Q3 24 | $89.3M | $168.6M | ||
| Q2 24 | $82.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $20.3M | — | ||
| Q3 25 | $30.8M | $5.4M | ||
| Q2 25 | $16.6M | $-4.8M | ||
| Q1 25 | $27.0M | $4.8M | ||
| Q4 24 | $-123.9M | — | ||
| Q3 24 | $24.7M | $-143.5M | ||
| Q2 24 | $-22.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 24.9% | 1.2% | ||
| Q3 25 | 39.1% | 3.5% | ||
| Q2 25 | 23.4% | 4.7% | ||
| Q1 25 | 27.0% | 1.2% | ||
| Q4 24 | 20.9% | 13.2% | ||
| Q3 24 | 31.8% | -82.8% | ||
| Q2 24 | 29.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 16.1% | — | ||
| Q3 25 | 26.6% | 3.0% | ||
| Q2 25 | 16.0% | -2.7% | ||
| Q1 25 | 28.8% | 2.8% | ||
| Q4 24 | -126.9% | — | ||
| Q3 24 | 27.6% | -85.1% | ||
| Q2 24 | -27.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.10 | $0.05 | ||
| Q3 25 | $0.16 | $0.12 | ||
| Q2 25 | $0.08 | $-0.11 | ||
| Q1 25 | $0.09 | $0.10 | ||
| Q4 24 | $-0.65 | $0.38 | ||
| Q3 24 | $0.09 | $-3.11 | ||
| Q2 24 | $-0.13 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.0M | $144.3M |
| Total DebtLower is stronger | $395.9M | — |
| Stockholders' EquityBook value | $47.0M | $653.9M |
| Total Assets | $531.0M | $1.2B |
| Debt / EquityLower = less leverage | 8.42× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $87.0M | $238.4M | ||
| Q3 25 | $6.3M | $246.3M | ||
| Q2 25 | $120.8M | $445.9M | ||
| Q1 25 | $255.9M | $493.6M | ||
| Q4 24 | $59.2M | $484.6M | ||
| Q3 24 | $39.1M | $453.8M | ||
| Q2 24 | $16.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $395.9M | $372.2M | ||
| Q3 25 | $279.9M | $376.7M | ||
| Q2 25 | $283.5M | $580.5M | ||
| Q1 25 | $287.0M | $583.4M | ||
| Q4 24 | $290.6M | $585.3M | ||
| Q3 24 | $294.1M | — | ||
| Q2 24 | $297.7M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $47.0M | $693.1M | ||
| Q3 25 | $71.0M | $727.2M | ||
| Q2 25 | $187.7M | $757.8M | ||
| Q1 25 | $319.8M | $798.5M | ||
| Q4 24 | $-131.6M | $778.3M | ||
| Q3 24 | $-13.4M | $749.6M | ||
| Q2 24 | $-41.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $531.0M | $1.3B | ||
| Q3 25 | $439.2M | $1.3B | ||
| Q2 25 | $547.6M | $1.5B | ||
| Q1 25 | $679.4M | $1.6B | ||
| Q4 24 | $479.1M | $1.6B | ||
| Q3 24 | $456.3M | $1.5B | ||
| Q2 24 | $435.0M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 8.42× | 0.54× | ||
| Q3 25 | 3.94× | 0.52× | ||
| Q2 25 | 1.51× | 0.77× | ||
| Q1 25 | 0.90× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $24.8M | — |
| Free Cash FlowOCF − Capex | $24.5M | — |
| FCF MarginFCF / Revenue | 19.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $140.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $24.8M | $43.7M | ||
| Q3 25 | $55.4M | $60.8M | ||
| Q2 25 | $37.5M | $12.0M | ||
| Q1 25 | $23.8M | $35.5M | ||
| Q4 24 | $29.5M | $33.1M | ||
| Q3 24 | $29.1M | $53.9M | ||
| Q2 24 | $15.8M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $24.5M | $43.5M | ||
| Q3 25 | $55.2M | $57.0M | ||
| Q2 25 | $37.3M | $9.3M | ||
| Q1 25 | $23.7M | $26.9M | ||
| Q4 24 | $29.3M | $31.0M | ||
| Q3 24 | $28.8M | $49.8M | ||
| Q2 24 | $15.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 19.5% | 22.1% | ||
| Q3 25 | 47.7% | 31.7% | ||
| Q2 25 | 35.8% | 5.1% | ||
| Q1 25 | 25.2% | 15.9% | ||
| Q4 24 | 30.0% | 16.6% | ||
| Q3 24 | 32.2% | 29.6% | ||
| Q2 24 | 19.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.2% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.3% | 1.1% | ||
| Q3 24 | 0.4% | 2.4% | ||
| Q2 24 | 0.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.22× | — | ||
| Q3 25 | 1.80× | 11.20× | ||
| Q2 25 | 2.25× | — | ||
| Q1 25 | 0.88× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GRND
| License And Service | $102.9M | 82% |
| Advertising | $23.1M | 18% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
